This installment of Law and the Public's Health considers the legal dimensions and impact of comparative effectiveness research, an advance in the development of evidence on clinical effectiveness that holds major promise for improving the quality and efficiency of health care.
This installment of Law and the Public's Health focuses on comparative effectiveness research (CER) and its implications for public health policy and practice. The Patient Protection and Affordable Care Act (PPACA) anticipates the implementation of CER as a matter of formal federal policy and practice. At the same time, CER raises important issues for public health.
BaCkgroUnD
The quality and relevance of evidence concerning the effectiveness of health-care services is crucial to policy questions related to clinical care, payment, and, ultimately, population health. The United States has lagged behind other nations in establishing a national policy to advance the production, use, and dissemination of evidence to shape key health policy decisions. For example, the National Institute for Health and Clinical Excellence in the United Kingdom uses CER to make coverage decisions under its publicly financed health-care system.
The Institute of Medicine (IOM), whose study of CER was highly influential in crafting the CER provisions in health reform, defines CER as the study of methods, including alternative approaches, to "prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care" and inform decisionmaking by "consumers, clinicians, purchasers, and policy makers." 1 The IOM definition is extremely broad and potentially encompasses not only head-to-head comparisons of different clinical treatments, but also approaches that use community-and population-level interventions to affect clinical conditions, such as improving housing quality for children with asthma or using structured nutritional and physical exercise interventions to help treat obesity.
Whether narrowly or broadly defined, CER and the evidence it generates can play a vital role for clinicians, patients, payers, public health professionals, and policy makers. 2 At the same time, opponents of a national policy to advance CER raise concerns regarding its potential to limit access and curb variation and innovation in health care to the detriment of individuals with rare conditions or those whose complex health conditions and/or social risks place treatment outside clinical norms. 3 The American Recovery and Reinvestment Act of 2009 (ARRA) 4 and the PPACA 5 significantly move the nation toward a national CER policy. In combination, the two laws expand the role of government and establish the financial and structural basis for the advancement of evidence in health care and health-care financing. 4 Their implementation can be expected to raise many questions regarding the scope and use of CER in numerous contexts: health-care delivery, public and private health insurance, and the interaction of clinical care and public health practice.
arra
The ARRA appropriated funding totaling $1.1 billion for CER and created a Federal Coordinating Council to make recommendations related to federal CER initiatives (replaced by an institute under the PPACA 6 ). These funds were allocated to the U.S. Department of Health and Human Services (HHS) ($400 million) and its agencies, the National Institutes of Health (NIH) ($400 million) and the Agency for Healthcare Research and Quality (AHRQ) ($300 million). Furthermore, ARRA required HHS, NIH, and AHRQ to accelerate research development and dissemination by (1) conducting, supporting, or synthesizing research that compares the clinical outcomes, effectiveness, and appropriateness of items, services, and procedures that are used to prevent, diagnose, or treat diseases, disorders, and other health conditions; and (2) encouraging the development and use of clinical registries, clinical data networks, and other forms of electronic health data that can be used to generate or obtain outcomes data. The ARRA also required HHS to contract with IOM (up to $1.5 million) to recommend national CER priorities. 7 In its June 2009 priorities report, the IOM expanded traditional CER to include not only comparison of clinical interventions (drugs or other forms of clinical treatment), but also alternative strategies that reflect population and community interventions. 1 During the debate regarding the ARRA, the use of CER information was a critical issue. The Conference Committee stated that funds could be used to "conduct or support research to evaluate . . . medical treatments and services . . .," but clarified that CER could not be used to "mandate coverage or reimbursement" policy. 8 This position was consistent with provisions first enacted by the Medicare Prescription Drug, Improvement and Modernization Act of 2003; the earlier Act prohibited HHS from conditioning pharmaceutical company participation in Part D to agreement to certain treatment approaches or from limiting payment for covered prescription drugs to particular treatments. 9 The ARRA House and Senate conferees restated this commitment to avoiding the use of CER to set across-the-board and individualized coverage and payment limits. 8 But the ARRA left many critical issues unresolved. First, who would bear responsibility for conducting and disseminating CER: the government, the private sector, or a public-private venture? Second, how, precisely, might evidence created by CER be used? Third, to what extent can treatment costs be considered? Finally, would the expansive IOM definition of CER be used to guide the advancement of a formal CER process to reach both population health and clinical interventions aimed at treating clinical conditions?
PPaCa
The PPACA answers several critical issues. The law authorizes the creation of a Patient-Centered Outcomes Research Institute (hereafter, the Institute) to conduct comparative clinical effectiveness research (CCER). 10 The law also appears to narrow the potential reach of the IOM definition of CER, although much is left to implementing agencies. The law defines CCER as "research evaluating and comparing health outcomes and the clinical effectiveness, risk, and benefits of two or more medical treatments, services, and items" 11 (emphasis added by the author). The term "medical treatments, services, and items" is defined not as broad "approaches" (as used by the IOM), but as "health care interventions, protocols for treatment, care management and delivery, procedures, medical devices, diagnostic tools, pharmaceuticals (including drugs and biologicals), integrative health practices, and any other strategies or items being used in the treatment, management, and diagnosis of, or prevention of, illness or injury in individuals." 12 How HHS further delineates this meaning will be important to follow.
The Institute
The PPACA establishes the Institute as a nonprofit corporation that is essentially government-sponsored, but not an "agency of, or established by" the U.S. government. 13 The PPACA thus delegates expansive CER powers, with the broad aim of advancing the "quality and relevance of evidence" that can be used by patients, clinicians, purchasers, and policy makers to make informed health-care decisions. In its charge to the Institute, the law also specifies that CCER must focus on the "manner in which diseases, disorders, and other health conditions can effectively and appropriately be prevented, diagnosed, treated, monitored, and managed through research and evidence synthesis." 14 (The use of the term "prevention" in this federal charge to the Institute suggests some tolerance for research involving approaches that are population health in nature rather than strictly clinical.) In addition, the PPACA requires the Institute to consider "variations in patient subpopulations" and disseminate "research findings with respect to the relative health outcomes, clinical effectiveness, and appropriateness of medical treatments, services, and items." 1 The use of research results in coverage and payment design, and insurance administration is not prohibited.
In addition, the PPACA moves beyond the ARRA by defining Institute duties to encompass the identification of national research priorities that take into account population health and disease burden factors, as well as the quality enhancement and cost-impact potential of new evidence. Thus, the PPACA makes cost an explicit factor for consideration. The Institute is also expected to establish a national research agenda and methodological standards and is further expected to assure that the research takes into account key subpopulation differences such as race/ethnicity, gender, age, comorbidity, variations in genetic and molecular subtypes, quality-oflife preferences, and different treatment modalities.
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Public Health Reports / November-December 2010 / Volume 125 Finally, the law emphasizes transparency, requiring that the Institute make research findings accessible to clinicians, patients, and the general public within 90 days of availability. Findings must convey the research in a manner that is useful to patients and providers; address considerations specific to certain subpopulations, risk factors, and comorbidities; and identify limitations of the research and what further research may be needed.
In a small nod to the ARRA's limitations on the use of evidence, the law provides that research findings should not be construed as mandates for practice guidelines, coverage recommendations, payment, or policy recommendations, while at the same time lifting any hard constraints on use. 15 (The Act does bar the release of any data that would violate the privacy of participants, suggesting a new and independent legal standard of privacy in health research involving individual patient information.)
Of perhaps greatest significance, the law mandates Institute funding rather than leaving funding to the uncertainties of the discretionary appropriations process. The PPACA establishes a Patient-Centered Outcomes Research Trust Fund through the end of fiscal year 2019 for the conduct of CCER, as well as for use by HHS, AHRQ, and NIH in supporting dissemination of research findings. 16 The sources of financing include the Federal Hospital Insurance Trust Fund, 17 the Federal Supplementary Medical Insurance Trust Fund, 18 the Treasury general fund, and fees on insured and self-insured health plans. 16 
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While the PPACA clearly resolves the key issue of who will be responsible for CER by establishing and funding the Institute, critical issues remain.
Priority-setting
One of the Institute's first tasks will be to determine national priorities and a research agenda, including research methodologies. Given the relative paucity and inexperience of existing CER efforts, particularly head-to-head clinical trials, as well as vastly divergent stakeholder (e.g., clinician, patient, medical and pharmaceutical manufacturer, and payer) interests and priorities, this task will be challenging. While these decisions will require a majority vote of the Institute's Board, they will be subject to significant and diverse stakeholder debate that will define the direction and utility of CER.
Use of the research
While the PPACA provides significant support, developing the research alone does not ensure its use. In addition, while the PPACA opens the door to more robust use of evidence, it also limits the use of CER by the Medicare program. For example, the HHS Secretary may use the research to make Medicare coverage decisions and to determine reimbursement or incentive programs based upon a comparison of the difference in the effectiveness of alternative treatments in extending an individual's life due to age, disability, or terminal illness. The research also may be used to apply differential Medicare copayments based on factors such as cost or type of service. However, the Secretary may not use the research to establish mandatory practice guidelines for individual coverage determinations or make population-wide coverage, payment, or policy decisions solely on the basis of CER. Nor can the Secretary use the evidence to develop or employ a "dollars-per-quality adjusted life year" or similar measure to determine what treatments are cost-effective. 19 The PPACA does not constrain the use of the research by other payers including Medicaid and the Children's Health Insurance Program. As such, other payers, private and public, may use the information to limit coverage, reimbursement, or incentive programs in ways that may be productive, but also that may be contrary to the goal of providing greater access to providers, treatments, and services and have a disparate impact on different populations.
Use of cost information
The use of cost information in CER is one of the most controversial issues. Supporters argue that without cost information, the utility of CER to inform clinicians, patients, and payers about the cost-benefit of various treatments will be limited. Opponents fear that the use of cost information will limit access to care and impede the development of new and innovative health-care technologies. While there are a number of mechanisms through which cost could be introduced as a factor (e.g., determining priorities, treatment, or payment decisions), the PPACA only authorizes clinically based CER. However, given the interest in reducing the rate of growth in health-care costs and the potential for CER to play a significant role in doing so by identifying and recommending use of the most cost-effective drugs, treatments, or therapies, the dialogue concerning cost information will continue.
Definition of CER
Underlying all of these issues will be the extent to which the PPACA is implemented in a manner that narrows the scope of research to medical interventions or, instead, in a manner that fosters population health interventions that bear directly on the prevention, lessening, or treatment of chronic conditions among the population. The law on this point is sufficiently ambiguous as to merit close scrutiny by public health practitioners. How the terms are defined will impact priority setting, the research agenda and methodology, and potential application of cost information. While immediate focus on clinical treatments will enable the use of available information from ongoing and future clinical trials, a broader vision of CER could foster the development of alternative nonclinical, populationbased strategies that achieve both improved health and better clinical outcomes.
